Citations 2
PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).
Tobinai, Kensei , Lin, Tongyu , Vanazzi, Anna , Hino, Masayuki , Shi, Yuankai , Mayer, Jiřı́ , Bermúdez, Carlos , Zhu, Jun , Bouabdallah, Kamal , Kattan, Joseph , Wu, Cassandra, Fan, Jenna, Louveau, Anne-Laure, Voi, Maurizio, Cavalli, Franco , Witzig, Thomas E. , Rigacci, Luigi , Ikeda, Takashi , Costa, Luciano J. , Belada, David
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7506-7506
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
Wang, Michael , Popplewell, Leslie , Collins, Robert H. , Winter, Jane N. , Kaminski, Mark , Bartlett, Nancy L. , Johnston, Patrick B. , Lister, John , Fanning, Suzanne, Tuscano, Joseph M. , Robeva, Anna, Fan, Jenna, Klimovsky, Judith, Cheung, Wing, Cherfi, Azzeddine , O’Connor, Owen A. , Goy, Andre Henri , Beck, J. Thaddeus , Kaya, Hakan , Bartlett, Nancy L , Winter, Jane N
British Journal of Haematology | March 3, 2014 | Volume: 165 | Issue: 4 | Pages: 510-518